Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | solute carrier family 6 (neurotransmitter transporter), member 2 | Starlite/ChEMBL | References |
Homo sapiens | nitric oxide synthase 1 (neuronal) | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | Sodium:neurotransmitter symporter family protein | solute carrier family 6 (neurotransmitter transporter), member 2 | 617 aa | 638 aa | 32.5 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Plasmodium falciparum | nitric oxide synthase, putative | 0.0091 | 0.7578 | 1 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0081 | 0.6183 | 0.5 |
Loa Loa (eye worm) | solute carrier family 6 member 4 | 0.0109 | 1 | 1 |
Schistosoma mansoni | norepinephrine/norepinephrine transporter | 0.0109 | 1 | 1 |
Plasmodium vivax | flavodoxin domain containing protein | 0.0081 | 0.6183 | 0.8159 |
Echinococcus multilocularis | serotonin transporter | 0.0109 | 1 | 1 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0091 | 0.7578 | 0.6596 |
Loa Loa (eye worm) | hypothetical protein | 0.0091 | 0.7578 | 0.7578 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0091 | 0.7578 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0091 | 0.7578 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0035 | 0 | 0.5 |
Giardia lamblia | Hypothetical protein | 0.0081 | 0.6183 | 0.5 |
Brugia malayi | FAD binding domain containing protein | 0.0056 | 0.2883 | 0.2883 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0091 | 0.7578 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0045 | 0.1395 | 0.5 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0035 | 0 | 0.5 |
Leishmania major | p450 reductase, putative | 0.0091 | 0.7578 | 1 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0091 | 0.7578 | 1 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0091 | 0.7578 | 1 |
Trichomonas vaginalis | NADPH fad oxidoreductase, putative | 0.0081 | 0.6183 | 0.8159 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0091 | 0.7578 | 0.7578 |
Echinococcus granulosus | serotonin transporter | 0.0109 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0109 | 1 | 1 |
Chlamydia trachomatis | sulfite reductase | 0.0056 | 0.2883 | 0.5 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0091 | 0.7578 | 0.6596 |
Brugia malayi | flavodoxin family protein | 0.0091 | 0.7578 | 0.7578 |
Leishmania major | cytochrome P450 reductase, putative | 0.0081 | 0.6183 | 0.8159 |
Brugia malayi | FAD binding domain containing protein | 0.0091 | 0.7578 | 0.7578 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0091 | 0.7578 | 0.6596 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0091 | 0.7578 | 0.5 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0035 | 0 | 0.5 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0045 | 0.1395 | 0.5 |
Loa Loa (eye worm) | norepinephrine transporter | 0.0109 | 1 | 1 |
Trypanosoma cruzi | p450 reductase, putative | 0.0091 | 0.7578 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0035 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0109 | 1 | 1 |
Loa Loa (eye worm) | serotonin transporter b | 0.0109 | 1 | 1 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0046 | 0.1488 | 0.0108 |
Onchocerca volvulus | 0.0109 | 1 | 0.5 | |
Entamoeba histolytica | type A flavoprotein, putative | 0.0035 | 0 | 0.5 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0091 | 0.7578 | 0.6596 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0091 | 0.7578 | 0.7185 |
Schistosoma mansoni | sodium/chloride dependent transporter | 0.0109 | 1 | 1 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0091 | 0.7578 | 1 |
Treponema pallidum | sodium- and chloride- dependent transporter | 0.0109 | 1 | 1 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0056 | 0.2883 | 0.2883 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0091 | 0.7578 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0109 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0091 | 0.7578 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0091 | 0.7578 | 1 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0056 | 0.2883 | 0.173 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0091 | 0.7578 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 0.49 uM | Inhibition of human nNOS expressed in baculovirus-infected insect sf9 cells assessed as conversion of [3H]-L-arginine to [3H]-L-citrulline preincubated for 15 mins with compound measured after 45 mins by scintillation counting | ChEMBL. | 22420844 |
IC50 (binding) | = 2.4 uM | Displacement of [3H]nisoxetine from human NET expressed in CHO cells after 120 mins by scintillation counting | ChEMBL. | 22420844 |
IC50 (binding) | = 54.1 uM | Inhibition of human iNOS expressed in baculovirus-infected insect sf9 cells assessed as conversion of [3H]-L-arginine to [3H]-L-citrulline preincubated for 15 mins with compound measured after 45 mins by scintillation counting | ChEMBL. | 22420844 |
IC50 (binding) | = 77.6 uM | Inhibition of human eNOS expressed in baculovirus-infected insect sf9 cells assessed as conversion of [3H]-L-arginine to [3H]-L-citrulline preincubated for 15 mins with compound measured after 45 mins by scintillation counting | ChEMBL. | 22420844 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.